Last updated: May 18, 2026
What Follistatin 344 is
Follistatin is an endogenous protein produced primarily in the gonads, pituitary, and liver. The “344” refers to the 344-amino-acid isoform (FS344). Other isoforms exist (FS288, FS315) with different tissue distributions and binding properties.
Follistatin is a single-chain glycoprotein with a high affinity for myostatin (GDF-8), activin A, and several BMP family members. Its primary biological role: regulating these signaling pathways through ligand sequestration.
Mechanism — myostatin inhibition
Myostatin (also called growth differentiation factor 8, GDF-8) is a member of the TGF-β superfamily that acts as a negative regulator of skeletal muscle mass. Naturally-occurring myostatin loss-of-function mutations produce dramatic muscle hypertrophy:
- Belgian Blue and Piedmontese cattle breeds (double-muscling)
- Bully whippets (heterozygous mutations)
- Rare human cases (Liam Hoekstra, the “Superman baby”)
Follistatin binds myostatin and prevents it from binding its receptor (ActRIIB). Result: removal of the brake on muscle growth.
Animal evidence
Multiple studies in rodents, sheep, and dogs show dramatic muscle mass increases (20-40%) with myostatin inhibition via follistatin gene therapy or recombinant protein. Effect sizes are larger than any anabolic steroid in equivalent studies.
Human evidence — limited
Phase 1/2 gene therapy trials for inclusion body myositis and Duchenne muscular dystrophy used follistatin gene constructs. Results were modest and didn’t translate to approved therapies. No human data exists for healthy adults using follistatin for muscle building.
Research dosing considerations
Reported research-community protocols use 100-200 mcg per day for 10-day cycles, with extended rest periods. These protocols extrapolate from rodent studies and are not clinically validated.
Safety considerations
Theoretical concerns:
- Cardiac muscle hypertrophy (myostatin is expressed in heart tissue)
- Tendon-muscle imbalance (rapid muscle growth without proportional tendon adaptation)
- Activation of latent malignancies (broad TGF-β pathway modulation)
- Unknown long-term effects on other TGF-β family signaling (which regulates wound healing, immune function, etc.)
Regulatory status
- US: Sold as research peptide; not FDA-approved
- WADA: Banned (myostatin inhibitors are prohibited)
- Note: Myostatin-targeting drugs from major pharma (Acceleron’s bimagrumab, Pfizer’s domagrozumab) failed Phase 3 muscular dystrophy trials with disappointing efficacy
Does follistatin actually work in humans?<br />
Limited evidence. Animal studies are dramatic but human clinical trials in muscle disorders have shown modest results. No data exists for healthy adults using follistatin for muscle building.
How does follistatin compare to other anabolic compounds?<br />
Different mechanism. Anabolic steroids work primarily through androgen receptor activation. Follistatin works by removing a negative regulator. Animal studies suggest follistatin could potentially produce larger effects than steroids, but human evidence is sparse.
What’s the difference between FS344 and FS315?<br />
Different isoforms produced by alternative splicing. FS315 has a C-terminal acidic tail not present in FS344, affecting tissue distribution and clearance.
Are there safety concerns?<br />
Yes. Cardiac hypertrophy, tendon issues, and broad TGF-β pathway effects are theoretical concerns. The clinical drug bimagrumab (similar mechanism via ActRIIB blocking) showed some safety signals in trials.